BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25672736)

  • 1. [Diagnosis and treatment of dementia: overview].
    Furukawa K; Ishiki A; Tomita N; Arai H
    Rinsho Shinkeigaku; 2014; 54(12):1171-3. PubMed ID: 25672736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
    Mullane K; Williams M
    Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type.
    Wagner M; Teichner G; Bachman DL
    Arch Clin Neuropsychol; 2003 Dec; 18(8):893-903. PubMed ID: 14609583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?
    Nichols L; Pike VW; Cai L; Innis RB
    Biol Psychiatry; 2006 May; 59(10):940-7. PubMed ID: 16487944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Contribution of molecular imaging research to innovative drug development].
    Shimada H
    Rinsho Shinkeigaku; 2014; 54(12):1174-7. PubMed ID: 25672737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of Alzheimer's disease: the present and the future.
    Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
    Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in Alzheimer's disease research].
    Hirai S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Apr; 18(2):55-61. PubMed ID: 9656234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
    Shoji M
    Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biomarker of dementia: clinical and preclinical diagnosis].
    Shoji M
    Nihon Rinsho; 2012 May; 70(5):857-63. PubMed ID: 22620013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid imaging: from benchtop to bedside.
    Wu C; Pike VW; Wang Y
    Curr Top Dev Biol; 2005; 70():171-213. PubMed ID: 16338342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutic Strategies for Dementia.
    Cacabelos R; Torrellas C; Carrera I; Cacabelos P; Corzo L; Fernández-Novoa L; Tellado I; Carril JC; Aliev G
    CNS Neurol Disord Drug Targets; 2016; 15(2):141-241. PubMed ID: 26831267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug development for overcoming dementia in Japan].
    Nakamura H
    Rinsho Shinkeigaku; 2014; 54(12):1181-3. PubMed ID: 25672739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.